

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Tue Jun 26 12:48:17 EDT 2007

=====

Application No: 10594940 Version No: 1.0

Input Set:

Output Set:

Started: 2007-06-25 19:40:45.760
Finished: 2007-06-25 19:40:45.804
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 44 ms
Total Warnings: 0
Total Errors: 0
No. of SeqIDs Defined: 13
Actual SeqID Count: 13

SEQUENCE LISTING

<110> Garber, Mitchell Ehren

<120> METHODS AND COMPOSITIONS FOR USE IN
EVALUATING AND TREATING NEOPLASTIC DISEASE CONDITIONS

<130> STAN-349

<140> 10594940

<141> 2007-06-25

<150> US2005/009926

<151> 2005-03-24

<150> 60/629,527

<151> 2004-11-18

<150> 60/558,953

<151> 2004-04-02

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> PRT

<213> human

<400> 1

Met	Glu	Ala	Ala	Asp	Ala	Ser	Arg	Ser	Asn	Gly	Ser	Ser	Pro	Glu	Ala
1				5					10					15	
Arg	Asp	Ala	Arg												
															20

<210> 2

<211> 17

<212> PRT

<213> human

<400> 2

Glu	Leu	His	Leu	Lys	Pro	His	Leu	Glu	Gly	Ala	Ala	Phe	Arg	Asp	His
1				5					10					15	
Gln															

<210> 3

<211> 18

<212> PRT

<213> human

<400> 3

Glu Gly Glu Gly Leu Gly Gln Ser Leu Gly Asn Phe Lys Asp Asp Leu
1 5 10 15
Leu Asn

<210> 4
<211> 17
<212> PRT
<213> human

<400> 4
Arg Glu Thr Ile Pro Ala Lys Leu Val Gln Ser Thr Leu Ser Asp Leu
1 5 10 15
Arg

<210> 5
<211> 17
<212> PRT
<213> human

<400> 5
Asp Pro Ala Lys Val Gln Ser Leu Val Asp Thr Ile Arg Glu Asp Pro
1 5 10 15
Asp

<210> 6
<211> 15
<212> PRT
<213> human

<400> 6
Arg Val Ala Ala Lys Arg Leu Lys Glu Gly Asp Thr Met Met Gly
1 5 10 15

<210> 7
<211> 19
<212> PRT
<213> human

<400> 7
Lys Thr Val Glu Ser Leu Glu Glu Thr Leu Lys Lys Ala Ser Pro Asp
1 5 10 15
Gly Tyr Asp

<210> 8
<211> 17
<212> PRT
<213> human

<400> 8
Thr Thr His Ser Ile Ser Asp Gly Lys Asp Leu Glu Lys Leu Leu Thr
1 5 10 15
Glu

<210> 9
<211> 24
<212> PRT
<213> human

<400> 9
Glu Tyr His Lys Val His Gln Met Met Arg Glu Gln Ser Ile Leu Ser
1 5 10 15
Pro Ser Pro Tyr Glu Gly Tyr Arg
20

<210> 10
<211> 23
<212> PRT
<213> human

<400> 10
Arg His Gln Leu Leu Cys Phe Lys Glu Asp Cys Gln Ala Val Phe Gln
1 5 10 15
Asp Leu Glu Gly Val Glu Lys
20

<210> 11
<211> 19
<212> PRT
<213> human

<400> 11
Asp Leu Glu Val Lys Asp Trp Met Gln Lys Lys Arg Arg Gly Leu Arg
1 5 10 15
Asn Ser Arg

<210> 12
<211> 30
<212> DNA
<213> human

<400> 12
ggatccatgg aagctgcaga tgctccagg 30

<210> 13
<211> 71
<212> DNA
<213> human

<400> 13

accggtgtgc atcctccgcc gccgcatacct ccgccgccgg cggctggggc ttcgttggac 60
ccaatcccgt t 71